Cerus announces new, four-year supply agreement with EFS

Cerus (CERS) Corporation announced the signing of a new, four-year supply agreement with Etablissement Francais du Sang, EFS, the French Blood Establishment, for the INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma as well as the next generation, LED-based INT200 illumination device. “We are proud to announce a new four-year supply agreement with the French Blood Establishment,” said Christian Boutemy, Cerus’ vice president of international commercial operations. “EFS has been a global leader in the adoption of pathogen inactivation technologies to help safeguard the blood supply and enhance patient safety. This agreement further underscores our shared, enduring commitment to ensuring safe transfusions for patients.”